There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nuvectra Corporation (NASDAQ:NVTR), Spark Therapeutics (NASDAQ:ONCE) and Myovant Sciences (NYSE:MYOV) with bullish sentiments.
Nuvectra Corporation (NVTR)
Piper Jaffray analyst Matthew O’Brien reiterated a Buy rating on Nuvectra Corporation yesterday and set a price target of $21. The company’s shares closed yesterday at $15.36.
According to TipRanks.com, O’Brien is a top 100 analyst with an average return of 27.2% and a 69.5% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Merit Medical Systems.
Nuvectra Corporation has an analyst consensus of Strong Buy, with a price target consensus of $22.
See today’s analyst top recommended stocks >>
Spark Therapeutics (ONCE)
SunTrust Robinson analyst Edward Nash reiterated a Buy rating on Spark Therapeutics yesterday and set a price target of $61. The company’s shares closed yesterday at $56.01.
According to TipRanks.com, Nash is a 4-star analyst with an average return of 15.9% and a 49.1% success rate. Nash covers the Healthcare sector, focusing on stocks such as Eloxx Pharmaceuticals Inc, Galmed Pharmaceuticals, and Sarepta Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spark Therapeutics with a $73.08 average price target, which is a 30.5% upside from current levels. In a report released yesterday, William Blair also maintained a Buy rating on the stock.
.
Myovant Sciences (MYOV)
Robert W. Baird analyst Brian Skorney reiterated a Buy rating on Myovant Sciences today and set a price target of $30. The company’s shares closed yesterday at $22.50.
According to TipRanks.com, Skorney is a 4-star analyst with an average return of 11.0% and a 56.8% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Melinta Therapeutics Inc, Reata Pharmaceuticals, and Sarepta Therapeutics.
Myovant Sciences has an analyst consensus of Strong Buy, with a price target consensus of $26, which is a 15.6% upside from current levels. In a report issued on July 24, Citigroup also maintained a Buy rating on the stock.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
